-
公开(公告)号：EP3349743A1
公开(公告)日：2018-07-25
申请号：EP16847549.9
申请日：2016-09-19
发明人： MIN, Jaeki , SCOTT, Daniel, C. , BHASIN, Deepak , SCHULMAN, Brenda, A. , SINGH, Bhuvanesh , HAMMILL, Jared, T. , GUY, R., Kiplin
IPC分类号： A61K31/17 , A61K31/445 , C07D211/58 , C07D401/12
CPC分类号： A61K31/4545 , A61K31/17 , A61K31/437 , A61K31/451 , A61K31/4525 , A61K31/454 , A61K31/506 , A61P15/16 , A61P31/04 , A61P31/12 , C07D211/58 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/06 , C07D405/12 , C07D409/14 , C07D417/04 , C07D417/06 , C07D471/04
摘要： In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
-
公开(公告)号：EP3337784A1
公开(公告)日：2018-06-27
申请号：EP16837721.6
申请日：2016-08-17
发明人： MOORE, Malcolm , SHIEH, Jae-Hung , SU, Tsann-Long , LEE, Te-Chang
IPC分类号： C07C275/42 , C07D215/42 , C07D219/08 , A61P35/02
摘要： Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymphoblastic leukemia (B-ALL)], lymphomas, small lung cell carcinoma (SCLC), sarcomas, and others.
-
公开(公告)号：EP3325100A1
公开(公告)日：2018-05-30
申请号：EP16828326.5
申请日：2016-07-15
IPC分类号： A61P35/00 , A61K31/437 , A61K31/475 , A61K39/395
CPC分类号： A61K31/713 , A61K31/4439 , A61K31/506 , A61K31/7105 , A61K31/711 , A61K45/06 , A61P35/00 , A61K2300/00
摘要： The present invention relates to methods and compositions for inhibiting growth and proliferation of cancer cells resistant to PI3K inhibition using a combination of PDK1, SGK1 and PI3K inhibitors. The present invention is also directed to methods of treating cancer in a subject exhibiting cancer cells resistant to PI3K inhibition, comprising administering inhibitors of PI3K in combination with inhibitors of PDK1 and/or SGK1 to the subject.
-
公开(公告)号：EP3317035A1
公开(公告)日：2018-05-09
申请号：EP16742091.8
申请日：2016-06-30
发明人： KIRCHER, Moritz , WALL, Matthew , HARMSEN, Stefan
CPC分类号： B22F1/0018 , A61K9/0009 , A61K9/5115 , A61K9/5192 , B22F9/24 , B22F2001/0037 , B22F2301/255 , B22F2998/10 , B22F2999/00 , B82Y30/00
摘要： The present disclosure, among other things, provides new technologies for preparation of anisotropic nanoparticle cores (e.g., anisotropic gold nanoparticle cores) and compositions thereof. Provided technologies show a number of advantages as compared with previously available options for preparing anisotropic nanoparticle cores, including, for example, that they typically utilize mild reaction conditions and, in many embodiments, only environmentally benign agents. The present invention therefore provides “green” nanoparticle technologies. Surprisingly, in many cases, the same set of reactants can be used, under modestly different conditions, to generate nanoparticle cores of different shapes. The present invention provides selection rules for reaction conditions that generate populations containing particular shapes of interest.
-
公开(公告)号：EP3177905A4
公开(公告)日：2018-04-18
申请号：EP15830230
申请日：2015-08-07
发明人： JUNGBLUTH ACHIM , FROSINA DENISE
CPC分类号： G01N1/36 , G01N1/44 , G01N2001/2873 , G01N2001/368
摘要： An exemplary tissue array, and a method for producing the same, can be provided which can include providing an accepter biological structure(s), providing a donor tissue(s), removing a portion(s) of the donor tissue(s), and removing a portion(s) of the accepter biological structure(s). The removed portion(s) of the accepter biological structure(s) can have a size that is substantially similar to a size of the removed portion(s) of the donor tissue(s). The removed portion(s) of the donor tissue(s) can be inserted into the accepter biological structure(s) at a location substantially corresponding to the removed portion(s) of the accepter biological structure(s).
-
公开(公告)号：EP3193865A4
公开(公告)日：2018-04-11
申请号：EP15842612
申请日：2015-09-18
发明人： MASSAGUE JOAN , BOIRE ADRIENNE , CHEN QING
IPC分类号： A61K31/4188 , A01K67/00 , A61K31/337 , A61P35/00
CPC分类号： A61K31/352 , A61K31/196 , A61K31/282 , A61K31/555 , A61K31/7105 , A61K45/06 , G01N33/5011 , G01N2333/705 , A61K2300/00
摘要： The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.
-
公开(公告)号：EP3180038A4
公开(公告)日：2018-04-04
申请号：EP15827785
申请日：2015-07-28
发明人： WALL MATTHEW A , SHAFFER TRAVIS , HARMSEN STEFAN , GRIMM JAN , KIRCHER MORITZ F
IPC分类号： A61K51/12 , A61K103/00 , A61K103/20 , A61K103/30 , B82Y15/00
CPC分类号： A61K51/1244 , A61K51/025 , A61K51/1251 , B82Y15/00
摘要： The present disclosure, among other things, provides new technologies for preparation of medical isotope labeled metal(loid) chalcogen nanoparticles for use in medical imaging and/or therapeutic applications. Provided technologies show a number of advantages as compared with previously available options for preparing and utilizing medical isotopes, including, for example, they utilize metal(loid) chalcogen nanoparticles that serve as universal binders (e.g., via covalent or non-covalent (e.g., chelate) bonds) for medical isotopes to provide medical isotope labeled metal(loid) chalcogen nanoparticles. Surprisingly, the same metal(loid) chalcogen nanoparticles may be used to bind (e.g., covalent or non-covalent e.g., chelation) bonding) a wide variety of different useful medical isotopes without the use of traditional chelating agents.
-
公开(公告)号：EP3280454A1
公开(公告)日：2018-02-14
申请号：EP16718099.1
申请日：2016-04-07
申请人： Memorial Sloan Kettering Cancer Center , Cornell University , The Curators of the University of Missouri
发明人： YOO, Barney , QUINN, Tom , BRADBURY, Michelle , WIESNER, Ulrich , LEWIS, Jason , MA, Kai , CHEN, Feng
CPC分类号： A61K47/6923 , A61K45/06 , A61K49/0058 , A61K49/1824 , A61K51/0478 , A61K51/10 , A61K51/1093 , A61K51/1251 , C07K16/40 , C07K2317/55 , C07K2317/569 , C07K2317/622
摘要： Disclosed herein are nanoparticle immunoconjugates useful for therapeutics and/or diagnostics. The immunoconjugates have diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution). In certain embodiments, the conjugates are silica-based nanoparticles with single chain antibody fragments attached thereto.
-
公开(公告)号：EP3271485A1
公开(公告)日：2018-01-24
申请号：EP16765779.0
申请日：2016-03-17
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/156
摘要： The invention relates generally to methods for diagnosis and treatment of follicular lymphoma or diffuse large B cell lymphoma. Specifically, the invention relates to detecting a lysine (K)-specific methyltransferase 2D (KMT2D) alteration to diagnose or treat follicular lymphoma or diffuse large B cell lymphoma.
-
公开(公告)号：EP3271398A1
公开(公告)日：2018-01-24
申请号：EP16716959.8
申请日：2016-03-16
IPC分类号： C07K16/30 , C12N15/13 , A61P35/00 , A61K39/395
CPC分类号： C07K16/3092 , A01K67/0275 , A01K2217/052 , A01K2217/15 , A01K2217/203 , A01K2227/105 , A01K2267/0331 , A61K39/0011 , A61P35/00 , C07K14/4727 , C07K16/2809 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C12N2800/30
摘要： Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.
-
-
-
-
-
-
-
-
-
搜索结果
578 条记录 (耗时 0.054 秒)
